Top entities: Zymeworks, Theravance Biopharma, BeOne Medicines, Jazz Pharmaceuticals.

What category does this event fall under?

Business — classified as earnings announcement.

What is the sentiment of coverage?

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Zymeworks announced financial results date · Zymeworks elected not to host call

Is this event still developing?

This is an active story, last updated Jul 16, 2026. Coverage continues to evolve.

Business earnings announcement

Zymeworks Q2 2026 results date

Q: When did this event occur?

First reported Jul 16, 2026; last updated Jul 16, 2026.

Q: What is the market impact?

General. The announcement is a routine earnings schedule update with no immediate market impact.

Analysis based on 6 articles · First reported Jul 16, 2026 · Last updated Jul 16, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The announcement is a routine earnings schedule update with no immediate market impact. The decision to skip the call due to the pending acquisition may cause minor uncertainty but is not expected to affect stock price significantly.

biotechnology

Event Summary

Zymeworks Inc. announced it will report second quarter 2026 financial results after market close on August 6, 2026. Due to the previously announced proposed acquisition of Theravance Biopharma, Zymeworks will not host an earnings conference call. The company expects to provide an update after the acquisition closes.

Key Actions

30 Zymeworks announced financial results date

20 Zymeworks elected not to host call

Entities Involved

stock

Zymeworks

Zymeworks is the subject of the announcement; it will report Q2 results and skip the earnings call due to the pending acquisition of Theravance Biopharma.

Importance 100.0 Sentiment 0.0

stock

Theravance Biopharma

Theravance Biopharma is the target of Zymeworks' proposed acquisition, which is the reason for skipping the earnings call.

Importance 50.0 Sentiment 0.0

priv

BeOne Medicines

BeOne Medicines is a partner with exclusive rights to develop and commercialize zanidatamab in certain territories; mentioned in the company description but not directly involved in this event.

Importance 10.0 Sentiment 0.0

stock

Jazz Pharmaceuticals

Jazz Pharmaceuticals is a partner with exclusive rights to develop and commercialize zanidatamab in certain territories; mentioned in the company description but not directly involved in this event.

Importance 10.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard